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There has been an explosion of knowledge in the epigenetics ﬁeld in the past 20 years.The
ﬁrst epigenetic therapies have arrived in the clinic for cancer treatments. In contrast,
much of the promise of epigenetic therapies for non-cancerous conditions remains in the
laboratories. The current review will focus on the recent progress that has been made in
understanding the pathogenic role of epigenetics in immune and inﬂammatory conditions,
and how the knowledge may provide much needed new therapeutic targets for many
autoimmune diseases. Dietary factors are increasingly recognized as potential modiﬁers
of epigenetic marks that can inﬂuence health and diseases across generations. The
current epigenomics revolution will almost certainly complement the explosion of personal
genetics medicine to help guide treatment decisions and disease risk stratiﬁcation.
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INTRODUCTION
Epigenetics is traditionally deﬁned as heritable gene expression
modiﬁcations that cannot be attributed to changes in the primary
deoxyribonucleic acid (DNA) sequence. The epigenetic machin-
ery is particularly important in organismal development where
stable and distinct cellular functions must be established from an
identical genotype. As such, efforts have been placed into decod-
ifying the epigenetic language that is believed to regulate gene
expression. In a growing amount of complex diseases, researchers
are identifying epigenetic dysregulation that can be associated to
their pathogenesis, and although studies can vaguely shed light
on whether epigenetics as a product or an effect of the disease,
evidence indicates that epigenetics play a substantial role in the
susceptibility of an individual to these diseases.
Deoxyribonucleic acid methylation and histone modiﬁcations
are considered to be the two major epigenetic mechanisms, but
other epigenetic mechanisms include alterations in ribosomal
DNA (rDNA) and microRNA (miRNA). Both non-covalent and
covalent modiﬁcations can affect chromatin structure and cause
remodeling to it in such a way that it inﬂuences heritable gene
expression. DNA methylation leads to gene silencing, whereas
posttranslational modiﬁcations of histone proteins can lead to
either induction or repression of gene activity. These epigenetic
mechanisms are believed to be crucial for reading environmen-
tal stimuli and creating long-lasting changes that could be passed
onto future generations (Manolio et al., 2009). Genome-wide asso-
ciation studies (GWAS) are moving toward including epigenetic
analysis (epigenomics) alongside the analysis of single nucleotide
polymorphisms (SNPs) in individuals to build a more complete
hereditary proﬁle for complex diseases.
Epigenetic pathways have long been recognized as a major
player in oncogenesis. The inﬂuence of the epigenome have been
associated to many key aspects of cancer, such as malignant
self-renewal, differentiation blockade, evasion of cell death, and
tissue invasiveness (Dawson and Kouzarides, 2012). As such, the
development of epigenetic drugs to counter these aspects of can-
cer has been one of the focuses of cancer research. For example,
because cancerous conditions can stem from a complexity of
changes in epigenetic regulators, inhibitors of DNA methyltrans-
ferases and histone deacetylases (HDACs) have been approved by
the US Food and Drug Administration for therapeutic purposes.
However, now that a tremendous amount of evidence is mounting
to show that many other diseases are affected by the epigenome,
drug repositioning efforts have been launched to explore epi-
genetic therapies for non-oncology conditions (Best and Carey,
2010). This review aims to focus on the epigenetics of immune
diseases and to highlight the therapeutic potential of epigenetic
interventions.
DNA METHYLATION
Deoxyribonucleic acid methylation involves the covalent attach-
ment of a methyl group onto the C5 position of a cytosine residue
onCpG (cytosine-phosphate-guanine) islands (Figure 1). A group
of enzymes, DNA methyltransferases (DNMTs), catalyze the addi-
tion of the methyl group to the DNA; the DNMT family includes
DNMT1, DNMT3a, DNMT3b, and DNMT3l. DNA methylation
typically occurs during DNA replication to maintain methylation
patterns down cell lineages via hemimethylated DNA, but dur-
ing replication and embryogenesis, it is also possible for de novo
methylation of DNA to occur. The family of methyl-CpG-binding
proteins consists of six members thus far, MBD1–MBD4, Kaiso,
and methyl-CpG binding protein 2 (MeCP2) (Fan and Hutnick,
2005; Klose and Bird, 2006).
Feng and Fan (2009) concisely discussed four current mod-
els in which DNA methylation can mediate gene silencing. DNA
methylation can prevent the transcriptional activator binding to
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FIGURE 1 | DNA methylation.
the target DNA sequence which directly impedes transactivation
(Watt and Molloy, 1988). Next, the DNMT protein might be
physically linked to HDAC and histone methylase (HMT) pro-
teins, allowing the coupling of enzymatic activities (Fuks et al.,
2000). Third, DNA methylation within the gene body exerts a
repressive effect on transcriptional elongation—it can occur in
the promoter or downstream (Lorincz et al., 2004). Lastly, methyl-
CpG-binding proteins have been shown to directly recognize
methylated DNA and recruit transcriptional repressors to silence
and modify surrounding chromatin (Nan et al., 1997, 1998).
It is important to recognize that the epigenetics ﬁeld is rapidly
expanding and changes in other epigenetic processes, such as DNA
hydroxymethylation (implicated in DNA demethylation), may
be important in disease pathogenesis and are therefore poten-
tial therapeutic targets as well. Tet enzymes (Tet1/2/3) convert
5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) and
possibly 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC)
(Wu and Zhang, 2011; Huang et al., 2014). Tet3 has recently been
implicated in a study to signiﬁcantly contribute to hydroxyla-
tion of 5mC during development. The key ﬁnding in this study,
however, was on Tet1 and Tet2; the study shows that Tet1/Tet2-
deﬁcientmice are viable and produces fertile offspring but accrued
developmental defects attributed to a reduction in 5hmC and an
increase in 5mC that was also accompanied by hypermethylation
(Dawlaty et al., 2013). The epigenetic anomalies and disruption in
somatic genomic reprogramming in these mice embryonic stem
cells strongly suggest their role as regulators of DNA methylation
and potential as therapeutic targets for autoimmune diseases.
HISTONE MODIFICATIONS
Chromatin is described to form either euchromatin (DNA lightly
wrapped around histone proteins that form nucleosomes and typ-
ically contains the most active genes) or heterochromatin (the
tightly packed DNA). Enzymatic modiﬁcations to histones alter
the structure of chromatin and inﬂuence the expression and
repression of genes. The nucleosome is the basic repeat unit of
chromatin which contains two copies of each histone (H2A, H2B,
H3, and H4) that are wrapped by 146 base pairs of DNA (Li,
2002).
The posttranslational histone modiﬁcations include acety-
lation, methylation, phosphorylation, ubiquitination, ADP
ribosylation, deimination, proline isomerization, and sumoyla-
tion. Of these, acetylation and methylation have received the most
attention. These modiﬁcations determine the higher-order chro-
matin structure that can lead to both expression and repression
of genes (Jenuwein and Allis, 2001). There is a “histone code”
which is believed to be the combination of different histone mod-
iﬁcations that deﬁne different epigenetic marks and these would
then collectively generate the plasticity in gene expression among
individuals.
The most well-studied histone modiﬁcation is the acetyla-
tion of lysine residues. It is a reversible process catalyzed by two
enzymes, the histone acetylase (HAT) and HDAC (Figure 2). The
presence of an acetyl group decreases interaction between nega-
tively charged DNA and the positively charged histone tail which
results in a less compact nucleosome, enables easier access for
transcription factor complexes (Feng and Fan, 2009). Therefore,
removal of the acetyl group by HDAC leads to gene transcription
repression.
The effect of methylation of histones is based on how many
methyl groups (mono-, di-, or tri-) are added onto the lysine
residue. Tri-methylationonH3K4 (histone 3, lysine 4) is associated
with transcriptional activation whereas the same methylation on
H3K9 or H3K27 are highly indicative of transcriptional inhibition
(Kouzarides, 2007). Methylation of histones is reversible through
a process called histone demethylation (Shi et al., 2004; Klose et al.,
2006).
microRNA
Deoxyribonucleic acidmethylation andhistonemodiﬁcations reg-
ulate short non-coding RNA called miRNAs that in turn regulate
gene expression post-transcriptionally. However, a different sub-
set of miRNAs behaves in the opposite way and can regulate the
expression of epigenetic machines, such as the aforementioned
DNMTs and HDACs, and polycomb group genes (Sato et al.,
2011). These miRNAs are short in length, ranging between 19
and 25 nucleotides, and they are non-coding RNAs that partic-
ipate in RNA interference (RNAi) machinery via binding to its
target mRNA to decrease its translation (by guiding it to degrada-
tion or suppression) and thus making those transcripts less stable.
FIGURE 2 | Histone modification: acetylation.
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RNA polymerase II (pol II) transcribes miRNA genes into pri-
mary miRNA transcripts that require further processing prior to
its export from the nucleus (Lee et al., 2004).
In the past few years, the research interests in miRNAs and their
role in regulation and participation of the epigenetic machinery
have shown to be constructive for the deeper understanding of
what the function of these short non-coding sequences encom-
pass that inﬂuence autoimmunity. For example,miRNAsmiR-23b,
miR-30a have been shown to be downregulated and miR-146a
and miR-214 upregulated in autoimmune disease samples such
as human lupus, rheumatoid arthritis (RA), osteoarthritis (OA),
and murine models of autoimmunity [experimental autoimmune
encephalomyelitis (EAE), MRL/lpr, collagen-induced arthritis
(CIA)] (Zhu et al., 2012b). Most interestingly, this study found that
in human ﬁbroblast-like synoviocytes,mouse primary kidney cells
and astrocytes, miR-23b can be downregulated by IL-17. How-
ever, miR-23b was found to be a suppressor of IL-17-associated
autoimmune inﬂammation (IL-17, TNF-α, IL-1β-induced NF-
κB activation) through speciﬁc target binding of TGF-β-activated
kinase 1/MAP3K7 binding protein 2 (TAB2) and TAB3 which is an
inhibitor of NFκ-B subunit α (IKK-αa). Through these ﬁndings, it
was evident that miRNAs play an intricate role in the modulation
of autoimmune pathogenesis that involves itself being an effector
and regulator simultaneously. A thorough discussion on miRNAs
and epigenetics has recently been done by Sato et al. (2011) to fur-
ther highlight the importance of miRNAs emerging from other
studies.
EPIGENETICS IN IMMUNE DISEASES
Immune diseases are typically described as disorders that cause
hypo- or hyper- reactivity of the immune system. Autoimmune
diseases fall into the category of immune system hyperactivity
where the body produces autoantibodies and attack the “self,”
which can cause extensive damage to various tissues, depending
on the type of autoimmunity. The trigger to most autoimmune
diseases in individuals is still unknown, but the growing research
in monozygotic twins consistently shows that many diseases have
relatively low concordance rate (<25%), indicating that genetics
are not the only factor in inheriting and developing the disease.
Similarly, genetic changes identiﬁed by GWAS so far account for
only a small component of the heredity of autoimmune diseases.
This has developed a set of evidence that suggests the environment
and epigenetics play a crucial role in determining the development
of these diseases in genetically susceptible persons.
Increasing evidence suggest a critical role of epigenetic determi-
nation in immune cell development and function. These include
Th1/2 cell lineage development, regulatory T cell development and
function, and the expression of multiple cytokines including IL-2
and TNFα.
GENDER BIAS IN AUTOIMMUNE DISEASES
There is a clear gender bias in many autoimmune diseases
(Whitacre et al., 1999; Ray and Yung, 2011; Ngo et al., 2014).
For example, there are two to three times more women than
men affected by RA and multiple sclerosis (MS). The ratio is
even more acute in some other autoimmune diseases such as sys-
temic lupus erythematosus (SLE) and Sjogren’s syndrome, with
women outnumbering men by a ratio of 9–1. Endocrinological
differences are important contributors to the sexual dimorphism
seen in autoimmunity, including a role in gene-speciﬁc epige-
netic modiﬁcations of DNA and histones (Kaminsky et al., 2006).
DNA methylation is a central mechanism in silencing the majority
of genes on one of the two X chromosomes in female cells (X-
chromosome inactivation). Among females (XX) and the males
who have Klinefelter’s syndrome (XXY), the frequency of SLE is
∼14 times higher in those having two copies of theX-chromosome
than normal males (XY) who only possess a single copy of
the X-chromosome. Evidence of defective DNA methylation or
reactivation of silenced genes on the inactive X-chromosome in
female lupus patients led to the theory that there exists a “gene-
dose” effect from the X-chromosome which could also explain
the similar susceptibility of SLE found in Klinefelter’s syndrome
patients (Scoﬁeld et al., 2008). Similar to SLE, RA preferentially
affects female patients who have skewed X-chromosome inacti-
vation patterns. The same CD40L gene on the promoter of the
X-chromosome was demethylated in female RA CD4+ T cells but
was not observed in male RA patients (Liao et al., 2012). Over 80%
of systemic sclerosis (SSc) patients are also female. Studies have
shown that, in female SSc patients, the demethylation of elements
that regulate CD40L on the inactive X-chromosome lead to over-
expression of CD40L and may partially explain the gender bias
(Lian et al., 2012).
SYSTEMIC LUPUS ERYTHEMATOSUS
DNA METHYLATION
Systemic lupus erythematosus is an autoimmune disease charac-
terized by chronic or acute inﬂammation in multiple tissues of the
body. The inﬂammation is in part due to production of pathogenic
autoantibodies against nuclear self-antigens but the causes are still
unclear. The ﬁrst clue that epigeneticmechanismsmay be involved
in SLE pathogenesis came from the study of drug-induced lupus.
The exposure to certain medications such as hydralazine and pro-
cainamide has been shown to induce SLE as early as the 1940s; this
was one of the ﬁrst pieces of observation that suggested environ-
mental factors, acting through DNA methylation modiﬁcations,
can affect SLE development (Richardson, 1986; Deng et al., 2003).
Procainamide was subsequently shown to behave similarly as the
DNMT1 inhibitor 5-azacytidine (5-azaC) to induce lupus-like dis-
ease in murine models (Yung et al., 1995, 1996). Hydralazine was
shown to induce in vivo murine lupus via preventing DNMT1
upregulation by inhibition of the ERK (and potentially other) sig-
naling pathways in T cells (Deng et al., 2003). Collectively, many
studies onDNMTshave led to highlightingDNAmethylation as an
important epigenetic effect underlying SLE (Altorok and Sawalha,
2013).
Sunlight exposure is known to induce lupus activity, andphoto-
sensitivity remains a diagnostic criterion for the disease. A number
of studies have examined the effects of UV (particularly UVB)
irradiation on lupus andnormal T cells, and showed thatUVexpo-
sure can induce DNA hypomethylation and the upregulation of
selected T cell genes implicated in lupus, including LFA-1 (CD11a)
(Richardson et al., 1994; Zhu et al., 2013). An interesting study
looked at the role of growth arrest and DNA damage-induced
45α gene (GADD45α) in lupus CD4+ T cells. Using ultraviolet B
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irradiation, they found that the T cells with increased expression
of gadd45A, CD11a, and CD70 mRNA also had more autore-
activity and excessive B cell stimulation (Li et al., 2010). These
results strongly support the theory that environmental triggers
can cause the onset of autoimmune diseases; in this case, UV light
was shown to be capable of inducing gadd45A which could then
initiate a lupus ﬂare. Next to this, it is the promotion of DNA
demethylation in lupus CD4+ T cells that lead to the increased
expression of gadd45A, showing that the environment and epige-
netics work closely together to determine the expression of disease
in an individual.
Some researchers have focused on identifying differential
methylation patterns in T cells between lupus patients and healthy
controls (Jeffries et al., 2011). Subsequently, hypomethylation of
certain genes have been identiﬁed as important in lupus T cells,
such as ITGAL (CD11a) (Lu et al., 2002), CD40LG (CD40L)
(Callard et al., 1993), TNFSF7 (CD70) (Oelke et al., 2004), Killer-
cell immunoglobulin-like receptor (KIR2DL4) (Basu et al., 2009),
perforin (PRF1) (Blanco et al., 2005), and CD5 in lupus B
cells (Garaud et al., 2009). Basu et al. (2009) showed that killer
immunoglobulin like receptors (KIRs) that are normally expressed
on natural killer (NK) cells are aberrantly expressed on demethy-
lated CD4+ T cells similar to that observed in lupus CD4+ T cells.
This suggests that the demethylation on KIR promoters caused a
change inKIR expression thatmay be either stimulating or inhibit-
ing the killing and secretion of inﬂammatory cytokines in SLE.
A different study compared healthy B cells to lupus B cells and
found that CD5-E1B, one of two CD5 isoforms, was demethy-
lated in the presence of increased IL-6 stimulation—leading to the
compromised expression of CD5-E1A and causing an expansion
in the pool of autoreactive B cells (Garaud et al., 2009). Simi-
larly, a separate study validated that the Erk/DNMT1 pathway is
indeed defective due to the autocrine-loop that increases IL-6 sig-
naling in lupus B cells; therefore, blocking this pathway allowed
DNA methylation to occur and expression of HRES-1/p28 was
restored (Fali et al., 2014). Anumber of genome-wideDNAmethy-
lation studies on CD4 T cells in lupus patients also recently been
completed, and conﬁrmed global DNA hypomethylation, and
identiﬁed severe hypomethylation events near genes involved in
type 1 interferon regulatory factor (IFN) signaling (Jeffries et al.,
2011; Lin et al., 2012; Absher et al., 2013).
Interestingly, an earlier report suggests that treatment with 5-
azaC, a DNA hypomethylation agent, may inhibit some features
of autoimmunity in the MRL-lpr mouse model (Yoshida et al.,
1990). However, the therapeutic effects appear to be speciﬁc to
the one particular autoimmune mouse strain, suggesting that the
protective effect may be speciﬁc to defects associated with the lpr
gene.
HISTONE MODIFICATIONS
Similarly, studies have delved into looking at histone methyla-
tion and acetylation statuses of lupus T cells. Using chromatin
immunoprecipitation (ChIP),Zhang et al. (2010) looked atmono-
cytes from controls and lupus patients to create gene expression
arrays for H4 acetylation and found that it was signiﬁcantly
increased in lupus monocytes. Although the authors did not
draw detailed conclusions on this observation, it was suggested
that IFN-1 is in the affected pathway (Zhang et al., 2010). Hu
et al. (2008) looked at the global histone H3/H4 acetylation and
H3K4/H3K9 methylation in lupus CD4+ T cells and found global
hypoacetylation in both H3 and H4 while global hypomethyla-
tion and H3K9 was detected. More convincingly, the degree of
histone H3 acetylation correlated inversely with increased SLE
disease activity (Hu et al., 2008; Patel and Richardson, 2010).
Dai et al. (2007) had also identiﬁed that H3K27me3 marks play
a role in the pathogenesis of SLE by looking at active and inac-
tive SLE and RA patient peripheral blood mononuclear cells
(PBMCs). Interestingly, MRL/lpr mice (spontaneously develop a
lupus-like disease) that lack HDAC9 have decreased lymphopro-
liferation, less autoantibodies, and improved survival (Yan et al.,
2011).
As histones are a major class of autoantigens in SLE
(Burlingame et al., 1994), Liu et al. (2012) asked the question of
whether post translational modiﬁcations (PTM) on histones in
neutrophil extracellular traps (NETS) can induce autoantibodies
that target these speciﬁcPTMof histones in SLEpatients. Although
they had no signiﬁcant ﬁnding that can demonstrate this proposed
mechanism between NETS and PTM of histones in SLE patients,
they reported the presence of a signiﬁcant autoantibody reactivity
to acetyl-histone H2B (Liu et al., 2012).
microRNA
Anumber of studies have examined the relationship between aber-
rant miRNA levels and lupus disease. One study found that the
overexpression of miR-125 correlates to the reduction of DNMT1
protein expression in lupus CD4+ T cells (Zhao et al., 2011),
and another study reported overexpression of miR-126 in healthy
donor CD4+ T cells that led to hypomethylation and overex-
pression of genes CD11a and CD70 (Pan et al., 2010). Together,
these studies demonstrate the importance of understanding the
crosstalk between miRNA and DNA methylation as it regulates
the activity of immune cells and affects disease progression. One
study found that peripheral blood leukocytes from lupus patients
express high levels of miR-21 and miR-198, and low expression of
miR-184 and miR-17-5p (Dai et al., 2007). More recently, Lu et al.
(2013) isolated T cells from ﬁve lupus patients and ﬁve healthy
controls to compare the proﬁles of 270 human miRNAs, including
miR-146a, miR-125a, miR-126, miR-21, and miR-148a, all miR-
NAs that have previously been associated with lupus pathogenesis
(Tang et al., 2009; Pan et al., 2010; Zhao et al., 2010, 2011; Sta-
gakis et al., 2011). Instead, they reported that there was a decrease
expression of miR-145 and an increased expression of miR-224;
consequentially, the drop in miR-145 expression in Jurkat cells
led to the suppression of STAT-1 expression which is associated
to lupus nephritis. On the other hand, the spike in miR-224
expression in Jurkat cells led to the decreased expression of the
API5 molecule which is believed to facilitate cell apoptosis and
contribute to lupus pathogenesis (Lu et al., 2013). Others have
suggested that miR-146a may contribute to aberrant type 1 IFN
expression in lupus by targeting signaling proteins (Tang et al.,
2009). The number of reports linking different miRNA to autoim-
munity is growing rapidly. At present, the precise pathogenic
and therapeutic role of miRNA in lupus disease pathogenesis is
unclear.
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EPIGENETIC THERAPEUTICS FOR SLE
Although much is now known about the epigenetic mechanisms
of lupus and epigenetics-based therapies have entered into clin-
ical practice, it is disappointing that much of the basic research
in the ﬁeld has not resulted in clinical trials in lupus or other
autoimmune diseases.
A number of drugs used in clinical practice are known to
inhibit HDACs, including valproic acid for epilepsy, and vorino-
stat and romidepsin for cutaneous T cell lymphoma. Although
these have not been tried in lupus patients, it is interesting to
note that there have been case reports of patients taking valproic
acid developing lupus-like diseases. Although an American Col-
lege of Rheumatology meeting abstract reported that valproic acid
may prevent skin disease and reduce kidney disease severity in
murine lupus, the results have not been formally published to date.
Interestingly, others have reported that valproic acid may reduce
proteinuria and the onset of glomerulosclerosis in a non-immune
kidney injurymurinemodels (VanBeneden et al., 2011; Brilli et al.,
2013), suggesting that any beneﬁcial effect of the drug may not
be lupus-speciﬁc. HDAC inhibitors (HDACis) such as suberoy-
lanilide hydroxamic acid (SAHA) and trichostatin A (TSA) have
also been shown to ameliorate SLE disease (e.g., nephritis) in mice
(Mishra et al., 2003; Reilly et al., 2008). TSA is largely an immuno-
suppressive imposer on T cells, but it is a promising potential in
treating SLE as most research points to aberrant behaving T cells
is caused by hypomethylation leading to overexpression of certain
genes, fueling T cell activity.
An early study used cytarabine, a cytidine analog that also
increases DNA methylation, as a treatment for refractory cuta-
neous lupus in a small pilot human study. Although there was
relapse in the disease during the fourth week of 2 of the 3 tested
cases, treatment with cytarabine was associated with the rapid
improvement of refractory cutaneous lupus in all the treated
patients (Yung and Richardson, 1995).
RHEUMATOID ARTHRITIS
Rheumatoid arthritis is a complex autoimmune disease where
synovial ﬁbroblasts interact with immune cells that lead to joint
destruction. The disease is characterized by synovial hyperplasia,
production of selected autoantibodies such as rheumatoid factor
and anti-citrullinated protein antibody, and systemic inﬂamma-
tion involving multiple organs outside the joints (McInnes and
Schett, 2011; Choy, 2012). The RA synovial ﬁbroblasts (RASFs)
produce an array of inﬂammatory cytokines and chemokines
which then further contributes andprogresses the systemic inﬂam-
mation. In a SCID mouse model, these synovial ﬁbroblasts were
capable of migrating from joint to joint, strongly suggesting that
they are involved in encouraging local inﬂammation to spread sys-
temically. More interestingly in the same study, it was proposed
that these synovial ﬁbroblasts carry an aggressive phenotype and
can spread it to other joints when they “metastasize” and interact
with the healthy synoviocytes (Lefevre et al., 2009).
DNA METHYLATION
The earliest clue suggesting an etiologic role of DNA methy-
lation in RA came from a 1990 study showing T cells from
patients with RA have hypomethylated DNA (Richardson et al.,
1990; Sanchez-Pernaute et al., 2008). A subsequent study found
retrotransposon elements in rheumatoid synovial ﬂuid that are
normally regulated by DNA methylation (Neidhart et al., 2000).
Others have since reported hypomethylated IL-6 promoter in RA
peripheral blood cells (Nile et al., 2008). A recent genome-wide
methylation study of peripheral blood cells from RA patients also
implicated aberrant DNA methylation as a key pathogenic process
in the disease (Liu et al., 2013).
Both DNA hypomethylation and hypermethylation have been
reported in RASFs, and its activation and aggressive phenotypes
are associated to epigenetic differences between the healthy con-
trol, RA patients, and OA patients. The synovial ﬁbroblasts were
found to have different DNA methylome signatures when com-
paring RASFs and OASFs to healthy synovial ﬁbroblasts; however,
between RASF and OASF, their methylome signatures were also
distinguishable from one another. The unique aggressive phe-
notype attributed to RASF may be a useful tool for diagnosing
patients and possibly become a therapeutic target. More impor-
tantly, among the 207 identiﬁed hypo- or hyper- methylated genes
in ﬁbroblast-like synoviocytes isolated from the site of RA disease
patients, hypomethylation was traced to multiple pathways that
relate to cell migration, focal and cell adhesion, transendothelial
migration, as well as extracellular matrix interactions (Nakano
et al., 2013). Any methylation changes at these genes can therefore
potentially affect RA disease progression. Another study found
that a signiﬁcant reduction in S-adenosyl methionine (SAM) in
RASFs as compared to OASFs may be due to increased recy-
cling of polyamines and explain the global DNA hypomethylation
observed in RASFs (Karouzakis et al., 2012).
HISTONE MODIFICATIONS
Trenkmann et al. (2011) obtained OASFs and RASFs to study
the expression, regulation, and function of the histone methyl-
transferase enhancer of zeste homolog 2 (EZH2). EZH2 was
overexpressed in RASFs as compared to OASFs, and in pursuit of
the downstream effectors of this pathway, they found that secreted
frizzled-related protein 1 (SFRP1), an inhibitor of Wnt signaling
that is associated with the activation of RASF was its target gene.
And although EZH2 is capable of generating the trimethyl mark
on H3K27, its overexpression did not seem to inﬂuence global his-
tone trimethylation in the RASFs (Trenkmann et al., 2011; Klein
and Gay, 2013).
Grabiec et al. (2010) set out to investigate whether the admin-
istration of HDACis would counterproductively induce further
inﬂammation in diseases such as asthma, chronic obstructive
pulmonary disease, or RA. They used TSA and nicotinamide,
both HDACis, to inhibit class I/II HDACs or class III sirtuin
HDACs and found that they could block the production of IL-6
and TNF-a in macrophages from both RA patients and healthy
controls. This ﬁnding supports the notion that HDACis can selec-
tively and effectively suppress proinﬂammatory growth factors,
chemokines and cytokines that fuel RA patient disease progression
(Grabiec et al., 2010).
microRNAs
Stanczyk et al. (2008) found that the increased expression of miR-
155 and miR-146a in RASFs treated with TNFα was higher than
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those inOASFs. Fromtheseﬁndings, the authors conclude it is pos-
sible that the inﬂammatory environment can be altering miRNA
expression proﬁles in resident cells of RA joints, spreading the
phenotype. In a different study with the same lab, they reported
elevated expression of miR-203 in RASFs than in OASFs and
healthy controls. Furthermore, they found that DNA demethyla-
tion achieved via 5-azaC also elevated the expression of miR-203,
showing that there is methylation-dependent regulation of miR-
203 expression in RASFs (Stanczyk et al., 2011). More recently,
Murata et al. (2013) reported that they found higher plasma con-
centrations of miR-24 and miR-125a-5p in RA patients than
in either SLE or OA patients; therefore, they are also potential
diagnostic markers of RA.
An interesting study set out to deﬁne miRNAs expression pro-
ﬁles of naïve and memory regulatory T cells (Tregs), including
conventional naïve and memory T cells (Tconvs) in RA patients
and healthy controls. They reported ﬁnding unique miRNA
expression signatures that could provide a subclassiﬁcation of T-
cell subsets associated to the disease. Speciﬁcally, they were able to
identify 5 miRNAs, miR-146a, miR-3162, miR-1202, miR-1246,
and miR-4281, to be signiﬁcantly enriched in both naïve and
memory Tregs. On the contrary, three miRNAs, miR-142-5p, let-
7c, and miR-590-5p were menially present in both Treg subsets
(Smigielska-Czepiel et al., 2014). This study demonstrated that
the inﬂammatory state of RA joints may be inﬂuenced by the T
cell subset composition in the synovial ﬂuid.
EPIGENETIC THERAPEUTICS FOR RHEUMATOID ARTHRITIS
There have been many experimentally used drugs that target epi-
genetic mechanisms that contribute to RA pathogenesis. DNMT
inhibitors such as 5-azaC was used to treat normal SF and
this reproduced RASF phenotype (Kooistra and Helin, 2012).
TSA and nicotinamide, both HDAC inhibitors, were separately
used to reduce TNF-α which in turn reduces IL-6 expression
in macrophages isolated from the PBMCs of RA patients (Gille-
spie et al., 2012). Others have shown that targeting HDACs, using
HDACi such as valproic acid, can mitigate the severity of murine
chronic inﬂammatory arthritis (Chung et al., 2003), in part via
improving regulatory T cell function (Saouaf et al., 2009). These
show potential therapeutic value, because they can reduce or dis-
rupt the production of inﬂammatory signals that fuel RA disease
activity. Another promising study silenced SIRT1 and promoted
apoptosis in RASFs from synovial tissues and cells from RA
patients (Niederer et al., 2011).
SYSTEMIC SCLEROSIS
Systemic sclerosis is a rare autoimmune disease with an incidence
of 0.002% but severe in its pathology—the 9 year survival rate
when internal organs are involved is 39% (Nikpour et al., 2010). It
is characterized by microvascular dysfunction, progressive ﬁbro-
sis of skin and/or internal organs, and immune abnormalities
in microvascular endothelial cells, T lymphocytes, B lympho-
cytes, and ﬁbroblasts. Although the disease’s cause is still widely
unknown, microvascular injury is believed to begin the cascade of
events in disease progression. As the microvascular injury leads to
endothelial activation, leukocytes are recruited and leads to T and
B lymphocytes to secrete a cocktail of cytokines, chemokines, and
autoantibodies. These agents then activate ﬁbroblasts for wound
healing which may then lead to tissue ﬁbrosis (Varga, 2008; Castro
and Jimenez, 2010).
DNA METHYLATION
Abnormalities in DNA methylation is associated with SSc. DNMT
inhibitors such as azacytidine can demethylate endothelial nitric
oxide synthases (eNOS) which is reduced in SSc patients, and
thus, is a possible therapeutic target (Matouk and Marsden, 2008).
Other studies look at DNA methylation in ﬁbroblasts that con-
tribute to the excessive deposition of collagen and extracellular
matrix and how DNMT inhibitors such as 5-aza-2′-deoxycytidine
(2-deoxy-5-azaC; 5-Aza-CdR; decitabine) can reverse this pathol-
ogy in SSc ﬁbroblasts (Wang et al., 2006). More recently, a study
isolated dermal ﬁbroblasts in six diffuse cutaneous SSc (dSSc)
patients, six limited cutaneous SSc (ISSc) patients and compared
them to healthy controls and identiﬁed thousands of differentially
methylated CpG sites in both dSSc and ISSc patients. They per-
formed pathway analysis of the shared differentially methylated
genes and reported a signiﬁcant upregulation in a set of genes
involved with extracellular matrix-receptor interaction and focal
adhesion (Altorok et al., 2014b). Altogether, the data provides a
useful platform for future studies to look at novel therapeutic
targets for both forms of the disease.
HISTONE MODIFICATIONS
Astudy that started out trying to identify autoantibodies in the sera
of SSc patients instead revealed the lack of autoantibody against
HDAC-3 which is detected in normal individuals. They concluded
that the anti-HDAC-3 antibody must be protective in nature
(Kuwatsuka et al., 2009). Another group investigated histonemod-
iﬁcations in B cells to study their potential role in SSc pathogenesis,
and they found global histone H4 hyperacetylation and global
histone H3K9 hypomethylation. These changes in histone mod-
iﬁcations were correlated to higher expression of JHDM2A and
downregulation of HDAC2, HDAC7, and SUV39H2. Impor-
tantly, global H4 acetylation positively correlated with disease
activity while HDAC2 was negatively correlated to skin thickness
(Wang et al., 2013). This was a promising ﬁnding, as an epigenetic
machine was indirectly found to control a symptom found in SSc
pathogenesis.
microRNAs
Another approach researchers have taken is to look at miRNAs
that can inﬂuence the development of SSc ﬁbrosis. miR-21, miR-
31, miR-146, miR-503, miR-145, and miR-29b have been linked
to SSc ﬁbrosis. miR-21 and miR-145 have already been identi-
ﬁed as regulators of genes related to ﬁbrosis such as, SMAD7,
SAMD3, and COL1A1 (Zhu et al., 2012a). Honda et al. (2012)
reported that in SSc ﬁbroblasts, miR-196a expression is TGF-b
mediated, and miR-196a inhibitor leads to the overexpression of
type I collagen in normal ﬁbroblasts. This correlated with how
patients who had lower serum miR-196a levels had a much more
exacerbated set of SSc symptoms than those who did not have
lower miR-196a levels (Honda et al., 2012). Makino et al. (2012)
analyzed serum samples from SSc, SLE, and several other dis-
eases to compare to healthy controls in order to identify useful
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diagnostic biomarkers; miR-142-3p serum levels were signiﬁ-
cantly higher in SSc than all others, making it a potential SSc
biomarker.
EPIGENETIC THERAPEUTICS FOR SYSTEMIC SCLEROSIS
The data summarized above support a scenario where aberrant
epigenetic control may lead to the excessive accumulation of der-
mal extracellular matrix proteins that is the hallmark of SSc. Wang
et al. (2006) demonstrated that HDAC inhibitors can repress col-
lagen suppressor gene FL11 and restore normal collage expression
in SSc ﬁbroblasts. The promoter of FL11 is hypermethylated in
SSc ﬁbroblasts which leads to suppression of its transcription;
therefore incubating it with 5-aza increases its transcription and
decreases release of collagen (Jungel et al., 2011). This is solid evi-
dence that portrays the anti-ﬁbrotic effect of DNMT inhibitors.
TSA primarily reduces all transcripts of HDACs and is especially
potent toward the inhibition of HDAC7 (Dokmanovic et al., 2007),
possibly making it a speciﬁc and targetable component of SSc
pathogenesis.
SJÖGREN’S SYNDROME
Sjögren’s syndrome (SS; SjS) is an autoimmune disease charac-
terized by the dysfunction of exocrine glands and lymphocytic
inﬁltrations, particularly the labial (minor salivary) and lacrimal
glands which leads to the hallmark symptoms of SS—xerostomia
(dry mouth) and keratoconjunctivitis sicca (dry eyes). Other clin-
icalmanifestations involve parenchymal organs such as the kidney,
lung, and liver (Mavragani and Moutsopoulos, 2014). Primary SS
(pSS), where the disease occurs alone, can be characterized via
the detection of circulating autoantibodies against the sicca syn-
drome (SS) and ribonucleoprotein (RNP) particles (Ro/SSA and
La/SSB). On the other hand, secondary SS (sSS) is when the dis-
ease is accompanied by other autoimmune diseases such as RA or
SLE and ﬁnding biomarkers to distinguish between patients who
have sSS remains a challenge.
DNA METHYLATION
Similar to a subset of autoimmune diseases, demethylation agents
have long been demonstrated as potent inducers of SS. Cannat
and Seligmann (1968) administered hydralazine and isoniazid to
mice, and this resulted in the development of SS accompanied by
SLE and RA immunological features that simultaneously exhib-
ited “antinuclear factors (ANF).” These antinuclear antibodies
disappeared in certain mice 2 months after the discontinuation
of drug treatment. Since then, several groups have looked at
the global DNA methylation in several types of SS cells. Thabet
et al. (2013) recently showed that there is a reduced global DNA
methylation in salivary gland epithelial cells (SGEC), peripheral T
cells, and B cells from pSS patients when compared to healthy
control biopsies. This reduction was associated to a sevenfold
decrease in DNMT1 as well as a twofold increase in Gadd45-α,
strongly indicative of a pathogenic role for epigenetics in SS. In
the same study, an in vitro co-culture experiment showed that
DNA hypomethylation in SGECs may be in part due to B cells
causing alterations to the PKCδ/Erk/DNMT1 pathway. Therefore,
the authors concluded that inﬁltrating B cells may be contributing
to the demethylation process—congruent to the ﬁndings from an
older study that showed that SS patients treated with rituximab
(an anti-CD20 antibody that depletes B cells) led to higher global
DNA methylation levels after 4 months of drug administration
(Devauchelle-Pensec et al., 2007).
Two separate studies reported that treatment with 2-deoxy-
5-azaC increases aquaporin 5 (AQP5) expression in the human
salivary gland (SG) ductal cell line NS-SV-DC (Motegi et al.,
2005) and restores salivary function in the murine aging model
C57Bl/6CrSlc (Yamamura et al., 2012). However, contrary to the
notion of using demethylating drugs to restore salivary function,
a more current study conﬁrmed that AQP5 is not repressed but
overexpressed in SGEC of SS patients, and it was shown that anti-
muscarinic type 3 receptor (α-M3R) suppresses AQP5 trafﬁcking
to the membrane which contributes to the keratoconjunctivi-
tis sicca in SS patients (Lee et al., 2013). Altorok et al. (2014a)
performed a genome-wide DNA methylation analysis of naïve
CD4+ T cells from pSS patients and reported 553 hypomethy-
lated and 200 hypermethylated CpG sites when compared to
healthy controls. The highlighted differentially methylated genes
included LTA (encodes for lymphotoxin α or TNF-β), RUNX1
(runt-related transcription factor that may be linked to lym-
phoma predisposition in SS patients), a subset of interferon
signature pathway genes, and also a group of genes that encode
for membrane water channel proteins. Yin et al. (2010) had shown
that similar to SLE patients, CD70 (TNFSF7) in pSS CD4+ T
cells are hypomethylated and thus overexpressed, contributing to
autoreactivity.
HISTONE MODIFICATIONS
Although the effect of CD70 upregulation in pSS CD4+ T cells
has yet to be investigated, Zhou et al. (2011) analyzed the histone
modiﬁcations in the TNFSF7 promoter region of SLE patients
and linked it to a global histone H3 and H4 hyperacetylation and
increased dimethylation of H3 lysine 4 (H3K4me2). Both these
results positively correlated to disease activity. Because SS is closely
associated to SLE, ﬁndings like these and all the other chromatin
links to SLE disease, suggests that targeting aberrant histone mod-
iﬁcations in SS patients may also be a feasible treatment pathway
(Konsta et al., 2014).
microRNAs
Similarly to histone modiﬁcations, very little research has been
performed to study the miRNA regulation of SS progression, their
potential role in disease, and as targets of therapy. It is however
gaining attention. For example, Pauley’s group linked increased
expression of miR-146a in human monocytic THP-1 cells to an
increase in phagocytic activity and suppression of inﬂammatory
cytokine production, and this ﬁnding was used to deduce that
the increase in miR-146a expression in SS patients may be con-
tributing to the pathogenesis of the disease (Pauley et al., 2011).
The expression of miR146a and miR146b were measured along
with their downstream target genes IRAK1, IRAK4, and TRAF6
in PBMCs of pSS patients to compare to healthy controls. The
study reported overexpression of miR146a/b and TRAF6 while
IRAK1 expression was decreased, leading them to propose TRAF6
as a more speciﬁc SS biomarker than miR146a/b (Zilahi et al.,
2012). Other groups have been focusing on identifying that there
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are differentially expressed miRNAs between the minor SGs of
SS patients and those of healthy controls (Alevizos et al., 2011;
Tandon et al., 2012), and these studies have established that miR-
NAs are indeed potential biomarkers of SS. More interestingly,
Alevizos et al. (2011) used Ingenuity Pathways Analysis to predict
the most likely targets of some of these miRNAs and found that
various neurologic function were the main targets—leading the
authors to suggest that the miRNA control over neurologic regu-
lation of SGs may be the underlying pathogenesis of SS. Among
SGs, SGECs, and PBMCs of SS patients and controls, Kapsogeor-
gou et al. (2011) reported that certainmiRNAs (prediction analysis
resulted in 11humanmiRNAs thatwere likely to targetRo/SSAand
La/SSB autoantigens) were differentially expressed. The authors
pointed out that the elevated expression of miR-181a, miR-200b,
and miR-223 in SS may be part of a negative feedback loop that
regulates autoantigen expression of Ro/SSA and La/SSB.
TYPE 1 DIABETES
DNA METHYLATION
Type 1 diabetes (T1D) is an autoimmune disease where T-cell
mediated destruction of insulin-secreting β cells causes insulin
deﬁciency and leads to an increased level of glucose in blood
and urine. The disease concordance rate in monozygotic twins
ranges between 13 and 67.7%, and this has been taken to suggest
that both environmental factors and epigenetics are potentially
involved (Huber et al., 2008). However, the large range of varia-
tion in riskmay also be due to human leukocyte antigen genotypes,
and studies show that low-risk HLA genotypes do correlate to
less destruction of the β cells (Spoletini et al., 2007). Nonetheless,
researchers have found differences when investigating the differ-
ential methylation patterns between T1D patients and healthy
controls in the seven CpGs proximal to the insulin gene pro-
moter (Fradin et al., 2012). Another recent study has shown that
T1D patients have decreased DNA methylation in the insulin-like
growth factor binding protein-1 (IGFBP-1) that correlates with
increased circulating IGFBP-1 levels and the presence of diabetic
nephropathy (Gu et al., 2014).
HISTONE MODIFICATIONS
Aside from DNA methylation, T1D pathology has also been asso-
ciated to histone modiﬁcations. A study that used curcumin to
observe changes in histone modiﬁcation in diabetic rats were
fruitful and found that next to increasing histone acetylation
on H3, it signiﬁcantly decreased blood urea nitrogen, creati-
nine, and increased albumin—all of which are markers of diabetic
nephropathy in T1D (Tikoo et al., 2008). Miao et al. (2014) used
ChIP to proﬁleH3K9 acetylation,H3K4 trimethylation, andH3K9
dimethylation in bloodmonocytes and lymphocytes fromdiabetes
patients. The aim was to see if epigenetics is associated to glycemic
history and metabolic memory in T1D patients, and the results
allowed the authors to claim that there is at least potential in link-
ing epigenetic changes to metabolic memory in T1D (Miao et al.,
2014).
microRNAs
Various miRNAs have been linked to the pathogenesis of T1D
and are associated to β-cell death (Dang et al., 2013). This has
been strongly supported by studies such as the elucidation on
the NF-κB-miR-21-PDCD4 axis that regulates pancreatic β cell
death. The presence of miR-21 decreases the level of PDCD4which
can enable cell death, and there can essentially be a “block” to
the destruction of the precious β cells that secrete insulin (Ruan
et al., 2011). The growing interest in linking miRNA regulation
to T1D pathogenesis has led a group to analyze Tregs and other
T cells in diabetic patients, and it was found that miRNA-146a
had enhanced expression while eight other miRNAs, miR-20b,
miR-31, miR-99a, miR-100, miR-125b, miR-151, miR-335, and
miR-365 had decreased expression in Tregs (Hezova et al., 2010).
Developing this type of miRNA signature in Tregs is important for
expanding the possibility of using miRNAs as therapeutic targets
in T1D.
EPIGENETIC THERAPEUTICS FOR T1D
While there have been little research done on testing epigenetic
drugs on T1D models, there was a study that inhibited class I and
class II HDACs with TSA which led to an enrichment of endocrine
progenitor cells and β cells. On the contrary, inhibiting class I
HDACs with valproic acid instead enhances endocrine progenitor
and α-cell pool (Haumaitre et al., 2008; Bramswig and Kaestner,
2012). As Bramswig concisely placed it, further work must be
done so that diabetes-speciﬁc epigenetic proﬁles will be clearly
established to distinguish between non-, early-, and late- diabetic




Multiple sclerosis is characterized as a chronic inﬂammatory, neu-
rodegenerative disease of the brain and spinal cord. Its cause is
largely unknown, although there are genetic inheritance impli-
cations, the low concordance rate in identical twins of 6–30%
have led many to believe that there are other etiological factors
and epigenetics at play (Koch et al., 2013). Epigenetics research in
MS has primarily focused on miRNA, but there are studies that
have begun to point at the signiﬁcance of DNA methylation in
MS as well. A study analyzed 56 genes for differential methylation
between healthy controls and patients with MS and found that
15 of the 56 genes contained methylation statuses that could be
used to distinguish between MS patients who are in remission and
those in later, more exacerbated stages of the disease (Liggett et al.,
2010). Other promising research looking at the role of epigenetics
in MS have identiﬁed the overexpression of DNMT3a as a possible
cause of neuronal cell death due to its ability to induce apop-
tosis in those cells. Although it has not yet been implemented
in the EAE or any other models of MS, the authors interest-
ingly pointed out that DNMTs, enzymes that participate in the
mechanism that regulate DNA methylation in neurons, could be
equivalently seen as amechanismof neurodegeneration (Chestnut
et al., 2011).
HISTONE MODIFICATIONS
Similar to Liggett’s study, Pedre et al. (2011) looked at histone
acetylation patterns in the white matter and early MS lesions to
look for therapeutic targets. The study reported that chronic MS
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patients shifted toward acetylation, but this especially occurred in
a subset of female patients. Most intriguing was that a signiﬁcant
level of acetylation of H3 was detected in the peripheral white
matter (PPWM) but decreased H3 acetylation was reported in
remyelinating lesions. This ﬁnding could lead to biomarkers that
distinguish between different types or stages of remyelination, as
the authors had pointed out.
microRNAs
A study developed miRNA expression proﬁles from patient
whole-blood samples that could help differentiate patients in the
relapsing-remitting (RMMS) phase of the disease from healthy
individuals with the use of miR-145 as a biomarker of RMMS
(Keller et al., 2009). Researchers looking at miRNA for potential
epigenetic therapeutics have observed that miRNA dysregulation
seems to favor proinﬂammatory activity which promotes dis-
ease progression. The miRNA proﬁle of active and inactive MS
lesions were analyzed and found to contain 28 miRNAs in active
lesions and 35 miRNAs in inactive lesions that were dysregulated
when compared to healthy controls (Junker et al., 2009). miRNA
expression proﬁling have inspired many other studies to attempt
narrowing down the pathological effects of miRNA dysregulation.
It has been shown that miR-155 and miR-326 are associated with
T-cell differentiation, and this led to a study that studied how
miR-155 enhances inﬂammatory T cell development in autoim-
mune diseases—reporting high levels of miR-155 in activated
CD4+ T cells that could also possibly contribute to the produc-
tion of inﬂammatory cytokines in dendritic cells (O’Connell et al.,
2010).
EPIGENETIC THERAPEUTICS FOR MULTIPLE SCLEROSIS
Histone deacetylases inhibitor, such as TSA, has reduced spinal
cord inﬂammation, demyelination, neuronal and axonal loss in
EAE models, and thus it has potential as a treatment option for
MS (Camelo et al., 2005). However, HDAC inhibitors used at the
systemic level have shown tonegatively affect the generationof new
myelin, because HDAC is crucial to developmental myelination
(Marin-Husstege et al., 2002; Shen et al., 2005).
Chirivi et al. (2013) have proposed citrullination as a target for
epigenetic intervention in MS and other inﬂammatory diseases;
they postulate that shielding citrullinated histone epitopes, which
play a large role inNET formation, canhelpprevent the intensiﬁca-
tion of the inﬂammatory response in MS and other inﬂammatory
diseases.
OBESITY AND TYPE 2 DIABETES
Obesity is closely associated with the development of both type
2 diabetes (T2D) and metabolic syndrome. There is growing
evidence that other than individual lifestyle choices, developing
obesity is also in part due to genetic disposition, especially epige-
netic processes. The “thrifty phenotype hypothesis” proposes that
the association between low birth weight and an increase in risk
of later disease is due to the fetus making adaptations (e.g., insulin
resistance) to survive the maternal malnourishment, leading to a
phenotype that would have to cope with a different, more afﬂu-
ent postnatal environment (Hales and Barker, 1992). Increased
DNA methylation has been associated with T2D in a Swedish
population (Gu et al., 2013). Interestingly, global DNA hyperme-
thylation has been linked to the presence of diabetic retinopathy
in T2D (Maghbooli et al., 2014). BCL11A gene polymorphism has
been established as a risk for T2D, and a recent study suggests
a possible male gender-speciﬁc association between BCL11A gene
methylation and T2D (Tang et al., 2014). Additionally, factors such
as cholesterol and the different types of fatty acids in the diet can
also impact on genome-wide DNA methylation patterns (Voisin
et al., 2014).
Two developmental scenarios are possible: either nutritional
limitation or excessive nutrition during early life, such as embryo
or fetal development, can play a role or increase their risk in cer-
tain diseases (Gluckman and Hanson, 2008). In order to exploit
this mechanism, studies have challenged fetal development in var-
ious animal models, such as rodents by reducing speciﬁc maternal
nutrition intake or administering a high fat diet to observe the
offspring phenotypic outcomes. Another study looked at how the
outcomeof a low-nutrition prenatal diet pairedwith post-weaning
high fat diet inﬂuenced adiposity in the offspring; the result was
that there was signiﬁcantly higher adiposity in the combination
conditions, as compared to the high fat diet alone (Vickers et al.,
2000). Recently, a GWAS on 459 individuals of European origin
was performed to explore the relationship between DNA methyla-
tion and BMI, and the analysis highlighted that increased BMI
in these individuals is linked to an increase in methylation at
the HIF3A locus in blood cells and in adipose tissue (Dick et al.,
2014). This study generates a lot of support for the relation-
ship between the epigenome and the development of obesity in
genetically susceptible individuals.
PRENATAL NUTRITION
During normal development, DNA methylation is crucial for
silencing speciﬁc genes at different stages and in differentiating
tissues. As such, maternal intake of macronutrients and micronu-
trients are believed to play a crucial role in the infant’s development
and also its adult susceptibility to late-life diseases.
Much of the current research has focused on the long term
effects of gestational macronutrition (calorie, fat, and protein)
in the offspring. Most human and animal studies have found
that almost any maternal nutrition stressors during pregnancy
increase the offspring’s risk of obesity, T2D, insulin resistance,
high blood pressure and heart disease. Additionally, paternal
diet may also play a role in determining the health of the off-
spring. An interesting study showed that paternal high-fat diet
can cause pancreatic beta cell dysfunction in female offspring,
likely through epigenetic mechanisms (Ng et al., 2010). Inter-
estingly, children born during the Dutch Hunger Winter in
Second World War have different DNA methylation patterns,
including hypomethylation of the IGF2 gene, compared to their
siblings born with better gestational nutrition (Heijmans et al.,
2008). Another study also found gender-dependent increased
DNA methylation of IL-10, LEP, ABCA1, GNASAS, and MEG3
genes in these subjects exposed to prenatal famine (Tobi et al.,
2009).
One of the hallmarks of the effect that maternal dietary sup-
plements can have on the offspring is vested in the viable yellow
agouti (Avy) mouse model. The Agouti gene encodes a paracrine
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signaling molecule that produces either black eumelanin (a) or
yellow pheomelanin (A). The Avy metastable epiallele resulted
from the insertion of an intracisternal A particle (IAP) murine
retrotransposon upstream of the transcription start site of the
Agouti gene, which in turn serves as an epigenetic biosensor for
nutritional and environmental alterations on the fetal epigenome.
Wolff et al. (1998) observed that upon supplementing the agouti
mice excess folic acid, vitamin B12, choline, and betaine prior
to pregnancy and then throughout, the offspring was veered
away from the phenotype of obesity, diabetes, and suscepti-
bility to tumors due to differences in methylation on the IAP
retrotransposon.
It is believed that maternal prenatal diets enact long-term con-
sequences through epigenetic mechanisms that can aid in the
offspring’s protection against diseases. Dietary factors can directly
alter the source or availability of methyl donors which can then
inﬂuence the developmental process. DNA methylation depends
on the levels of folic acid, methionine, choline, betaine, vitamins
B2, B6, and B12, and therefore, any dietary imbalance of these
agents can cause a change in methylation patterns (Haley et al.,
2011).
Delaney et al. (2013) showed recently that maternal micronu-
trient supplementation with methyl-donors can protect F1
ApoE −/− mice against atherosclerosis by inhibition of T cell
Ccr2 expression, a critical chemokine receptor that is central
to the pathogenesis of atherosclerosis. However, the study went
on to demonstrate that prolonged exposure to high-fat diet can
override the protective phenotype from the maternal prenatal
diet (Delaney et al., 2013). In contrast, a similar prenatal diet
was found to increase the severity of allergic airways disease in
a mouse model of asthma that persisted into the F2 generation
(Hollingsworth et al., 2008), and another study showed enhanced
colonic inﬂammation in a mouse model of inﬂammatory bowel
disease (Schaible et al., 2011). Besides the effect of the micronutri-
ent diet on DNA methylation, it is possible that the diet may exert
its effect via other epigenetic mechanisms or through changes in
the gut microbiome.
Intestinal commensal microbes have been key regulators of
immune system development and homeostasis (Ivanov and
Honda, 2012). The simplest demonstration of this was shown in
germ-free (GF) mice that struggle to develop gut-associated lym-
phoid tissues (GALTs) and isolated lymphoid follicles (Hamada
et al., 2002; Bouskra et al., 2008), indicating the necessity of the
presence of intestinal commensals for proper development of
immune components within the gut. Through subsequent stud-
ies, different commensals have been identiﬁed as crucial to the
induction and regulation of various immune cell populations such
as regulatory T cells (Tregs) (Feehley et al., 2012; Arpaia et al.,
2013; Furusawa et al., 2013), Th17 effector T cells (Ivanov et al.,
2008, 2009; Gaboriau-Routhiau et al., 2009; Yang et al., 2014),
and a more exhaustive list has been assembled by Kamada and
Nunez (2014). Markle et al. (2013) showed in a non-obese dia-
betic NOD mouse model of type 1 diabetes that the transfer of
gut microbiota from adult males to immature females led to the
alteration of recipient microbiota. Following this, testosterone
and metabolomic changes were associated to T1D protection in
the female pups through the decrease in insulitis and insulin
autoantibodies. This study emphasized the ability of the com-
mensal microbiobes to alter sex hormone levels which in turn
inﬂuenced autoimmune disease susceptibility in the context of
gender and its gene-associated risks.
ESTROGEN, EPIGENETICS, AND AUTOIMMUNE DISEASES
The gender bias seen in many autoimmune diseases has pointed
to a role for sex hormones in the pathogenesis of these dis-
eases. Much have already been written about the role of estrogens
and androgens in promoting autoimmune diseases through direct
effects on proinﬂammatory cytokine production. More recently, it
has been shown that epigenetic-mediated estrogen signaling also
plays a role in the human development (Jiang et al., 2013) and in
the pathogenesis of gender-dependent diseases (Frick et al., 2011;
Mann et al., 2011; Hervouet et al., 2013). Interestingly, bisphenol
A (BPA), an environmental estrogenic compound, is well known
to affect DNA methylation, disrupt imprinting (Susiarjo et al.,
2013), and worsen lupus disease in animal models (Sawai et al.,
2003).
SUMMARY AND CONCLUSION
Over the past two decades, research has been vested in identifying
epigenetic therapeutic targets in cancer and designing epigenetic
therapies to tackle oncological pathways, but growing evidence
showing that epigenetic pathways are pertinent to many other
non-oncological diseases have drawn the interest of scientists
(Table 1). The age of cancer research has observed a num-
ber of UFDA-approved drugs, including epigenetic drugs such
as HDAC inhibitors that were meant to maintain or normalize
acetylation states in cancer cells that have aberrant acetylation
patterns. Aforementioned, later studies have demonstrated that
HDAC inhibitors regulate a vast number of proteins of which
only a small percentage consists of histone proteins. This real-
ization opens both a potential to use HDAC inhibitors for
other diseases, like lupus and RA where it has been shown to
reduce proinﬂammatory cytokines, and it also raises awareness
in the potential backlash of targeting such a versatile and broad
epigenetic regulator.
As many others have mentioned, the difﬁculty in utilizing epi-
genetics in therapy is that these epigenetic regulators affect more
than the target of interest and has dose-limiting toxicities (Gray
and De Meyts, 2005). Next to this obvious problem, there is a
constant struggle to hunt for high-speciﬁcity biomarkers and to
also design therapeutics that are capable of targeting these spe-
ciﬁc markers. In many instances, while individual illnesses have
been associated with epigenetic changes it is not always clear
whether these associations are the cause or the consequence of
the diseases. Despite these complications, many research stud-
ies that were highlighted in this review have brought exciting
and promising evidence that epigenetics are applicable beyond
cancer therapy. GWAS are now progressing with the inclusion
of the epigenome to establish even more powerful sets of data
that can help distinguish non-Mendelian inheritance patterns. As
Best and Carey (2010) pointed out, epigenetic therapies carry
the potential to treat the disease as opposed to treating the
symptoms of the disease—to which many current therapies are
limited.
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Table 1 |Targets of epigenetic modifications associated with non-cancerous conditions.
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Understanding the epigenetic basis of disease may also be
important to disease management besides identifying epigenetic
changes as potential therapeutic targets. It is understood that
most complex diseases develop as a result of multiple cumulative
genetic factors interacting with beneﬁcial or harmful environmen-
tal agents. It is conceivable that, in the new era of personalized
medicine, epigenetic research will lead to the development of
individualized epigenomic proﬁling that can both inform risk
(e.g., risk of lupus or RA in a ﬁrst degree relative of an affected
individual) and guide therapies (e.g., which anti-inﬂammatory
or biologic agents, or likelihood of developing drug side-effects),
much like that is being promised by personalized genomic-based
medicine.
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